Liposomes as a Novel Bio-lubricant for Osteoarthritic Joints
Investment/ Collaboration Opportunity Highlights:
Having recently completed a successful proof-of-concept clinical trial, at December 2012, the company plans to launch a pivotal clinical study in 2013 and expects to have CE and FDA regulatory approval by Q3 2014. The requested investment amount of $5M will enable the company to conclude the coming clinical trial and to submit a market approval request to the EU. and US. authorities.
About the company
The company was founded in 2008 under the auspices of the RAD BioMed Accelerator. The company’s IP was developed by a multidisciplinary team from the Hebrew University of Jerusalem, the Technion Institute of Technology, and Hadassah.
Our products
Moebius Medical is developing the MM-II, a novel bio-lubricant that provides long-term effect by using liposomes as mechanical lubricants. Having completed a 40-subject clinical study, the MM-II shows great promise as the next-generation bio-lubricant for OA joints. Thanks to the special and unique consistency of liposomes, this innovative technology reduces joint damage and deterioration through the use of “biological ball-bearings” that provide mechanical lubrication, ease cartilage surface gliding, prevent further cartilage wear & tear, and eliminate additional joint damage and deterioration.
-
Extended duration of therapeutic effect compared to existing solutions
-
Prevents further cartilage wear & tear
-
Comprised of FDA approved compounds
-
Accelerated regulatory path due to characterization as a medical device (not a drug)
Development Milestones
Moebius Medical has conducted a successful proof-of-concept clinical trial at Hadassah Medical Center.
Contact details
Dr. Yaniv Dolev, CEO
+972-52-8911618
1586128900.png)